1. Home
  2. MIRM vs EPR Comparison

MIRM vs EPR Comparison

Compare MIRM & EPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$64.32

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Logo EPR Properties

EPR

EPR Properties

HOLD

Current Price

$50.20

Market Cap

4.4B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
EPR
Founded
2018
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
4.4B
IPO Year
2019
1997

Fundamental Metrics

Financial Performance
Metric
MIRM
EPR
Price
$64.32
$50.20
Analyst Decision
Strong Buy
Buy
Analyst Count
11
11
Target Price
$87.55
$57.06
AVG Volume (30 Days)
616.7K
620.3K
Earning Date
11-04-2025
10-29-2025
Dividend Yield
N/A
7.12%
EPS Growth
N/A
N/A
EPS
N/A
2.29
Revenue
$471,794,000.00
$707,150,000.00
Revenue This Year
$53.78
$5.11
Revenue Next Year
$19.91
$2.70
P/E Ratio
N/A
$21.77
Revenue Growth
53.66
3.73
52 Week Low
$36.88
$41.75
52 Week High
$78.55
$61.24

Technical Indicators

Market Signals
Indicator
MIRM
EPR
Relative Strength Index (RSI) 35.49 38.11
Support Level $63.66 $49.41
Resistance Level $66.77 $51.80
Average True Range (ATR) 2.99 0.93
MACD -0.69 -0.15
Stochastic Oscillator 9.63 20.14

Price Performance

Historical Comparison
MIRM
EPR

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About EPR EPR Properties

EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.

Share on Social Networks: